{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-099115","form_type":"8-K","ticker":"KTTA","cik":"0001841330","company_name":"Pasithea Therapeutics Corp.","filed_at":"2023-12-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.956313+00:00","generated_at":"2026-06-07T06:28:19.363960+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pasithea Therapeutics announces 1-for-20 reverse stock split effective January 2, 2024","bullets":["Reverse split ratio of 1-for-20; authorized shares reduced from 495M to 100M.","Effective at market open on January 2, 2024; CUSIP changes to 70261F202.","No fractional shares issued; cash payment based on 5-day average closing price pre-split.","All outstanding options, warrants, and convertible debt adjusted proportionately.","Board approved the split on Dec 21; shareholders authorized at Dec 19 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-099115","json":"https://secwatch.observer/filing/0001213900-23-099115.json","markdown":"https://secwatch.observer/filing/0001213900-23-099115.md","text":"https://secwatch.observer/filing/0001213900-23-099115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841330/000121390023099115/0001213900-23-099115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841330/000121390023099115/ea190815-8k_pasithea.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T06:28:19.363960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"196dc7eb36bfc57ed64c1f827173f53a78472fbc","claim":"Pasithea Therapeutics Corp.: Reverse stock split via Certificate of Amendment to Amended and Restated Certificate of Incorporation (effective 2024-01-02).","evidence_excerpt":"On December 28, 2023, Pasithea Therapeutics Corp. (the “Company”) filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), reflecting a one-for-twenty reverse stock split","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841330/000121390023099115/0001213900-23-099115-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-01-02"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}